Skip to main content
Top
Published in: Breast Cancer Research 6/2007

Open Access 01-12-2007 | Research article

International Web-based consultation on priorities for translational breast cancer research

Authors: Mitch Dowsett, Aron Goldhirsch, Daniel F Hayes, Hans-Joerg Senn, William Wood, Giuseppe Viale

Published in: Breast Cancer Research | Issue 6/2007

Login to get access

Abstract

Background

Large numbers of translational breast cancer research topics have been completed or are underway, but they differ widely in their immediate and/or future importance to clinical management. We therefore conducted an international Web-based consultation of breast cancer professionals to identify the topics most widely considered to be of highest priority.

Methods

Potential participants were contacted via two large e-mail databases and asked to register, at a Web site, the issues that they felt to be of highest priority. Four hundred nine questions were reduced by a steering committee to 70 unique issues, and registrants were asked to select the 6 questions they considered to be the most important.

Results

Votes were recorded from 420 voters (2,520 votes) from 48 countries, with 48% of voters coming from North America. Half of the voters identified themselves as clinicians, with the remainder being academics, research scientists, or pathologists. The highest priority was to identify molecular signatures to select patients who could be spared chemotherapy, which gained about 50% more votes than the second topic and was consistently voted top by voters in North America, Europe, and the rest of the world. Research scientists voted the determination of the role of stem cells in breast cancer development, progression, and treatment sensitivity as the most important issue, but this was considered the sixth priority for clinicians and fourth overall.

Conclusion

This exercise may bring a greater focus of research resources onto issues voted as top priorities.
Appendix
Available only for authorised users
Literature
1.
go back to reference Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001, 98: 10869-10874. 10.1073/pnas.191367098.CrossRefPubMedPubMedCentral
2.
go back to reference van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med. 2002, 347: 1999-2009. 10.1056/NEJMoa021967.CrossRefPubMed
4.
go back to reference Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD: Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol. 2003, 14: 1212-1214. 10.1093/annonc/mdg327.CrossRefPubMed Goldhirsch A, Colleoni M, Domenighetti G, Gelber RD: Systemic treatments for women with breast cancer: outcome with relation to screening for the disease. Ann Oncol. 2003, 14: 1212-1214. 10.1093/annonc/mdg327.CrossRefPubMed
5.
go back to reference Sparano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006, 7: 347-350.CrossRefPubMed Sparano JA: TAILORx: trial assigning individualized options for treatment (Rx). Clin Breast Cancer. 2006, 7: 347-350.CrossRefPubMed
6.
go back to reference Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, et al: Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006, 3: 540-551. 10.1038/ncponc0591.CrossRefPubMed Bogaerts J, Cardoso F, Buyse M, Braga S, Loi S, Harrison JA, Bines J, Mook S, Decker N, Ravdin P, et al: Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat Clin Pract Oncol. 2006, 3: 540-551. 10.1038/ncponc0591.CrossRefPubMed
7.
go back to reference Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE: Basal-like breast carcinomas : clinical outcome and response to chemotherapy. J Clin Pathol. 2006, 59: 729-735. 10.1136/jcp.2005.033043.CrossRefPubMedPubMedCentral Banerjee S, Reis-Filho JS, Ashley S, Steele D, Ashworth A, Lakhani SR, Smith IE: Basal-like breast carcinomas : clinical outcome and response to chemotherapy. J Clin Pathol. 2006, 59: 729-735. 10.1136/jcp.2005.033043.CrossRefPubMedPubMedCentral
Metadata
Title
International Web-based consultation on priorities for translational breast cancer research
Authors
Mitch Dowsett
Aron Goldhirsch
Daniel F Hayes
Hans-Joerg Senn
William Wood
Giuseppe Viale
Publication date
01-12-2007
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 6/2007
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1798

Other articles of this Issue 6/2007

Breast Cancer Research 6/2007 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine